Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05289687 · ClinicalTrials.gov registry record · Phase 2
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
A Phase 2 study of T-cell Acute Lymphoblastic Leukemia, sponsored by Eastern Cooperative Oncology Group.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05289687: Recruiting Phase 2 study of T-cell Acute Lymphoblastic Leukemia, sponsored by Eastern Cooperative Oncology Group.
NCT05289687 is a Phase 2 study of T-cell Acute Lymphoblastic Leukemia that is actively recruiting participants, run by Eastern Cooperative Oncology Group. The registered enrollment target is 20 participants, below the 60-participant average among 6 other T-cell Acute Lymphoblastic Leukemia trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05289687, a Phase 2 study of T-cell Acute Lymphoblastic Leukemia, is actively recruiting participants, sponsored by Eastern Cooperative Oncology Group.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.
Conditions Studied
Interventions
- DRUG Daratumumab / Hyaluronidase Injection
Study Locations (1)
Illinois
- Northwestern - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-05-25 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05289687
The ClinicalTrials.gov registry entry for NCT05289687 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 60-participant average among 6 other T-cell Acute Lymphoblastic Leukemia trials with a reported enrollment target (67% lower). The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with T-cell Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Daratumumab / Hyaluronidase Injection is the first listed.
NCT05289687 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT05289687 about?
NCT05289687 is a clinical study titled "Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL". In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.
What is the current status of trial NCT05289687?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2023-05-25. Estimated completion is 2027-06-30.
What conditions does trial NCT05289687 study?
This clinical trial studies the following conditions: T-cell Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT05289687?
The interventions under investigation include: Daratumumab / Hyaluronidase Injection (DRUG).
Who is sponsoring clinical trial NCT05289687?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05289687 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for T-cell Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
RECRUITING · Phase 2
-
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
RECRUITING · Phase 2
-
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
RECRUITING · Phase 1
-
Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
RECRUITING · Phase 1
-
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.